Prinbury Biopharm

Prinbury Biopharm is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of targeted protein degradation (TPD) therapies. The company leverages its proprietary P-Glue and P-Degrader platforms to discover and optimize molecular glues and Proteolysis-Targeting Chimeras (PROTACs) for challenging therapeutic targets. Its lead program, PB-101, is a next-generation BTK degrader designed to overcome resistance in B-cell malignancies and is currently in Phase 1 clinical trials. Prinbury's pipeline also includes molecular glues targeting GSPT1 for solid tumors and several undisclosed programs in oncology and immunology. Backed by prominent investors like Lilly Asia Ventures and Qiming Venture Partners, the company aims to transform the treatment landscape for "undruggable" proteins. Prinbury maintains research and development facilities in both Shanghai and Suzhou to support its internal discovery efforts.